Business & Industry
Business & Industry
AbbVie Secures $745M Haisco Deal to Expand Pain Drug Pipeline
AbbVie has entered into a global licensing agreement with China-based Haisco Pharmaceutical valued at up to $715 million, aiming to strengthen its presence in pain therapeutics. The Haisco deal grants AbbVie exclusive rights to develop, manufacture, and commercialize multiple...
Business & Industry
Aragen ChemiSHE Lab Launch Strengthens Women in Pharma R&D
Aragen has introduced ChemiSHE, positioning it as India’s first chemistry synthesis laboratory fully operated and led by women scientists. The facility was inaugurated on 8 April 2026 at the company’s Mallapur campus in Hyderabad, marking a targeted step by...
Business & Industry
Novo Nordisk OpenAI Partnership Accelerates Drug Development
Danish pharmaceutical major Novo Nordisk has entered into a strategic collaboration with OpenAI to embed artificial intelligence across its drug development operations, with the stated goal of accelerating the delivery of new treatments. Announced on Tuesday, the initiative is...
Business & Industry
Regeneron Telix Radiopharma Deal Targets Cancer Therapies
Regeneron Pharmaceuticals has entered into a strategic agreement with Telix Pharmaceuticals to jointly develop next-generation oncology treatments, in a deal valued at up to $2.1 billion in milestone payments. The radiopharma collaboration will combine Regeneron’s antibody-based discovery capabilities with...
Business & Industry
Drug Manufacturing Deals Shift to Europe Despite Tariffs
Biopharma companies are continuing to redirect production strategies toward Europe, even as U.S. policymakers attempt to strengthen domestic output through tariffs and onshoring measures. According to GlobalData, the latest data highlights a clear divergence in deal activity, with drug...
BioPharma
DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology
DeepCyte, a techbio company focused on advancing AI Drug Toxicology, has launched with $1.5 million in seed funding. The company is introducing two integrated solutions aimed at helping biopharma teams detect, predict, and explain drug toxicity directly in human...
Business & Industry
Hypercon Technology Deal Signed between Halozyme and Vertex
Halozyme Therapeutics has entered into a global exclusive partnership and licence agreement with Vertex Pharmaceuticals through its subsidiary Halozyme Hypercon, marking a new step in advancing drug delivery capabilities. The deal gives Vertex access to the Hypercon platform, which...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















